2. Search Result
Search Result
Results for "

bone resorption inhibitor

" in MedChemExpress (MCE) Product Catalog:

43

Inhibitors & Agonists

10

Peptides

2

Inhibitory Antibodies

7

Natural
Products

2

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-114275
    Justicidin B

    		Fungal Parasite Apoptosis Infection Cardiovascular Disease Cancer
    Justicidin B is a potent anticancer lignan and proapoptotic agent. Justicidin B is also a bone resorption inhibitor, and has strong antiviral, fungicidal, antiprotozoal effects. Justicidin B significantly inhibits platelet aggregation .
    Justicidin B
  • HY-B0119
    Risedronic acid sodium

    Risedronate sodium

    		 Others Others
    Risedronic acid sodium is a pyridinyl biphosphonate which inhibits osteoclast-mediated bone resorption.
    Risedronic acid sodium
  • HY-B0148
    Risedronic acid
    1 Publications Verification

    Risedronate

    		 Others Others
    Risedronic acid (Risedronate ) is a pyridinyl biphosphonate which inhibits osteoclast-mediated bone resorption.
    Risedronic acid
  • HY-P0090
    Calcitonin (salmon)
    1 Publications Verification

    Salmon calcitonin

    		 CGRP Receptor Cancer
    Calcitonin salmon, a calcium regulating hormone, is a dual-action amylin and calcitonin receptor agonist, could stimulate bone formation and inhibit bone resorption.
    Calcitonin (salmon)
  • HY-B0657
    Clodronic acid

    Clodronate

    		 Others Others
    Clodronic acid is an orally active bisphosphonate, which is used for researching osteoporosis and diseases associated with excessive bone resorption. Clodronic acid inhibits bone resorption through induction of osteoclast apoptosis. Clodronic acid is effective in the maintenance or improvement of bone mineral density .
    Clodronic acid
  • HY-B0148S
    Risedronic Acid-d4

    		Isotope-Labeled Compounds Others
    Risedronic Acid-d4 is the deuterium labeled Risedronic acid. Risedronic acid (Risedronate) is a pyridinyl biphosphonate which inhibits osteoclast-mediated bone resorption[1][2].
    Risedronic Acid-d4
  • HY-N5023
    Veraguensin

    		Others Metabolic Disease
    Veraguensin is a lignan compound derived from Magnolia sp.. Veraguensin can inhibit bone resorption
    Veraguensin
  • HY-122082
    Methopterin

    		Others Inflammation/Immunology
    Methopterin inhibits osteoclasts proliferation. Methopterin inhibits the activation and bone resorption function of osteoclasts, and induced osteoclasts apoptosis .
    Methopterin
  • HY-B0657A
    Clodronic acid disodium salt

    Clodronate disodium salt
    Clodronic acid (Clodronate) disodium salt, a first-generation bisphosphonate, is orally active osteoclastic bone resorption inhibitor. Clodronic acid disodium salt can be used in high bone turnover states, Paget ’s disease and osteolytic bone metastases .
    Clodronic acid disodium salt
  • HY-N9331
    Cimicifugoside H-1

    Cimicidanol-3-O-β-d-xyloside

    		 Others Metabolic Disease
    Cimicifugoside H-1, a cyclolanostanol xyloside, is a major constituent of C. foetida L. extract. Cimicifugoside H-1 inhibits bone resorption and ovariectomy-induced bone loss .
    Cimicifugoside H-1
  • HY-P4684
    Osteostatin

    PTHrP (107–111)

    		 PTHR
    Osteostatin, a fragment of parathyroid hormone-related protein (PTHrP) 107-111, promotes bone repair in animal models of bone defects and prevents bone erosion in inflammatory arthritis, inhibits collagen-induced arthritis and inhibits osteoclastic bone resorption directly. Osteostatin can be used for inflammation and immunology research .
    Osteostatin
  • HY-108685
    Alendronate sodium

    Alendronic acid monosodium salt

    		 Others Metabolic Disease
    Alendronate sodium is an orally active nitrogen-containing bisphosphonate. Alendronate sodium potently inhibits bone resorption. Alendronate sodium is used for the research of postmenopausal osteoporosis .
    Alendronate sodium
  • HY-10294
    Relacatib

    SB-462795

    		 Cathepsin Metabolic Disease Cancer
    Relacatib (SB-462795) is a novel, potent, and orally active inhibitor of human cathepsins K, L, and V with Ki values of 41 pM, 68 pM, and 53 pM, respectively. Relacatib inhibits endogenous cathepsin K in situ in human osteoclasts and human osteoclast-mediated bone resorption with IC50 values of 45 nM and 70 nM, respectively. Relacatib inhibits bone resorption in vitro in human tissue as well as in cynomolgus monkeys in vivo .
    Relacatib
  • HY-P2273
    Calcitonin (human)

    		CGRP Receptor Metabolic Disease
    Calcitonin (human) is a hypocalcemic hormone. Calcitonin can lower blood calcium levels and inhibit bone resorption. Calcitonin can be used in hypercalcemia or osteoporosis research .
    Calcitonin (human)
  • HY-B0631
    Alendronic acid
    2 Publications Verification

    		 Others Cancer
    Alendronic acid, a bisphosphonate, is a farnesyl diphosphate synthase (FDPS) inhibitor. Alendronic acid inhibits osteoclast-mediated bone resorption. Alendronic acid shows efficacy in postmenopausal osteoporosis, malignant hypercalcemia and Paget’s disease .
    Alendronic acid
  • HY-110318
    VUF11207 fumarate
    1 Publications Verification

    		 CXCR Inflammation/Immunology Cancer
    VUF11207 fumarate is a CXCR7 agonist that binds specifically to CXCR7. VUF11207 fumarate reduces CXCL12-mediated osteoclastogenesis and bone resorption by inhibiting ERK phosphorylation .
    VUF11207 fumarate
  • HY-A0020
    Eldecalcitol
    1 Publications Verification

    ED-71; 2-(3-hydroxypropoxy)-1,25-dihydroxyvitamin D3

    		 VD/VDR Apoptosis Metabolic Disease Inflammation/Immunology Cancer
    Eldecalcitol (ED-71) is an orally active vitamin D3 analogue, inhibits bone resorption and increases bone mineral density. Eldecalcitol (ED-71) displays anti-tumor effect and inhibits cell proliferation, migration and induces apoptosis by suppressing GPx-1 .
    Eldecalcitol
  • HY-126825
    NE21650

    		Others Metabolic Disease
    NE21650 potently inhibits farnesyl diphosphate (FPP) synthase. NE21650 is a weak inhibitor of isopentenyl diphosphate (IPP) isomerase. NE21650 is a potent inhibitor of protein prenylation in osteoclasts and macrophages and bone resorption in vitro .
    NE21650
  • HY-123370
    FR-167356

    		Proton Pump Metabolic Disease Cancer
    FR-167356 is a potent, orally active and selective vacuolar ATPase inhibitor with IC50 values of 170, 220, 370, and 1200 nM for osteoclast plasma membranes, macrophage microsomes, renal brush border membranes, and liver lysosomal membranes, respectively. FR-167356 inhibits bone resorption and ovariectomy-induced bone loss .
    FR-167356
  • HY-P1288
    Protein Kinase C (530-558)

    PKC fragment (530-558)

    		 PKC Others
    Protein Kinase C (530-558), a peptide fragment of protein kinase C (PKC), is a potent PKC activator. Protein Kinase C (530-558) significantly inhibits osteoclastic bone resorption .
    Protein Kinase C (530-558)
  • HY-P4798
    Osteostatin (1-5) amide (human, bovine, dog, horse, mouse, rabbit, rat)

    Human PTHrP(107-111) amide

    		 PTHR Others
    Osteostatin (1-5) amide (human, bovine, dog, horse, mouse, rabbit, rat) (Human PTHrP (107-111) amide) is a C-terminal parathyroid hormone-related protein fragment that can inhibit bone resorption .
    Osteostatin (1-5) amide (human, bovine, dog, horse, mouse, rabbit, rat)
  • HY-P0322
    GRGDSPK

    EMD 56574

    		 Integrin Cardiovascular Disease Metabolic Disease
    GRGDSPK (EMD 56574) is a peptide incluing Arg-Gly-Asp (RGD). GRGDSPK (EMD 56574) is an competitive and reversible inhibitory peptide for inhibiting integrin-fibronectin binding. GRGDSPK is used to study the role of integrins in bone formation and resorption .
    GRGDSPK
  • HY-B1246
    Thonzonium bromide
    5 Publications Verification

    		 Bacterial Proton Pump Infection
    Thonzonium bromide is an antibacterial agent that is structurally similar to Farnesol (HY-Y0248A). Thonzonium bromide is also a monocationic surface-active agent, which inhibits RANKL-induced osteoclast formation and bone resorption in vitro and prevents LPS-induced bone loss in vivo. Thonzonium bromide inhibits proton transport in a dose-dependent manner (EC50=69 μM) .
    Thonzonium bromide
  • HY-B0631S
    Alendronic acid-d6

    		Isotope-Labeled Compounds Cancer
    Alendronic acid-d6 is the deuterium labeled Alendronic acid. Alendronic acid, a bisphosphonate, is a farnesyl diphosphate synthase (FDPS) inhibitor. Alendronic acid inhibits osteoclast-mediated bone resorption. Alendronic acid shows efficacy in postmenopausal osteoporosis, malignant hypercalcemia and Paget’s disease[1].
    Alendronic acid-d6
  • HY-129337
    Reveromycin A

    		Antibiotic Fungal Apoptosis Infection Cancer
    Reveromycin A, a benzoquinoid antibiotic isolated from the genus Streptomyces, is a selective inhibitor of protein synthesis in eukaryotic cells. Reveromycin A inhibits bone resorption by inducing apoptosis specifically in osteoclasts. Reveromycin A has antiproliferative activity against tumor cell lines and antifungal activity .
    Reveromycin A
  • HY-12398
    TEI-9647

    		VD/VDR Metabolic Disease Inflammation/Immunology
    TEI-9647, a Vitamin D3 Lactone analogue, is a potent and specific vitamin D receptor (VDR) antagonist. TEI-9647 inhibits VDR/VDRE-mediated genomic actions of 1α,25(OH)2D3. TEI-9647 inhibits bone resorption and HL-60 cell differentiation induced by of 1α,25(OH)2D3. TEI-9647 has the potential for suppressing the excessive bone resorption and osteoclast formation in Paget's disease .
    TEI-9647
  • HY-P0322A
    GRGDSPK TFA

    EMD 56574 TFA

    		 Integrin Cardiovascular Disease Metabolic Disease
    GRGDSPK TFA (EMD 56574 TFA) is a peptide incluing Arg-Gly-Asp (RGD). GRGDSPK TFA is an competitive and reversible inhibitory peptide for inhibiting integrin-fibronectin binding. GRGDSPK TFA is used to study the role of integrins in bone formation and resorption .
    GRGDSPK TFA
  • HY-B0302
    Etidronic acid
    1 Publications Verification

    Etidronate; HEDPA; HEDP

    		 Apoptosis Metabolic Disease Cancer
    Etidronic acid (Etidronate) is an orally and intravenously active bisphosphonate. Etidronic acid inhibits resorption of bone, reduces arterial calcification and can be used for osteoporosis research. Etidronic acid has anticancer activity. Etidronic acid is a chelating agent and can be used to remove heavy metal in water .
    Etidronic acid
  • HY-N1956
    Rubiadin-1-methyl ether

    Rubiadin-1-methyl ether is a natural anthraquinone isolated from Morinda officinalis How, and inhibits osteoclastic bone resorption via inhibition on the phosphorylation of NF-κB p65 and the degradation of IκBα as well as decrease in the nuclear translocation of p65 .
    Rubiadin-1-methyl ether
  • HY-N6084
    Humulone

    α-Lupulic acid

    		 COX GABA Receptor Apoptosis Cardiovascular Disease
    Humulone (α-Lupulic acid), a prenylated phloroglucinol derivative, is a potent cyclooxygenase-2 (COX-2) inhibitor. Humulone acts as a positive modulator of GABAA receptor at low micromolar concentrations. Humulone is an inhibitor of bone resorption. Humulone possesses antioxidant, anti-angiogenic and apoptosis-inducing properties .
    Humulone
  • HY-103352
    L-006235

    L-235

    		 Cathepsin Metabolic Disease
    L-006235 (L-235) is a potent, selective, reversible and orally active inhibitor of cathepsin K, with an IC50 of 5 nM in bone resorption assay. L-006235 shows selectivity for cathepsin K (Ki=0.2 nM) over cathepsin B, cathepsin L, and cathepsin S (Ki=1, 6, and 47 μM, respectively). L-006235 can reduce collagen degradation and prevent bone loss .
    L-006235
  • HY-B0302A
    Etidronic acid disodium
    1 Publications Verification

    Etidronate disodium; HEDPA disodium; HEDP disodium
    Etidronic acid (Etidronate) disodium is an orally and intravenously active bisphosphonate. Etidronic acid disodium inhibits resorption of bone, reduces arterial calcification and can be used for osteoporosis research. Etidronic acid disodium has anticancer activity. Etidronic acid disodium is a chelating agent and can be used to remove heavy metal in water .
    Etidronic acid disodium
  • HY-149852
    Anti-osteoporosis agent-3

    		Others Inflammation/Immunology
    Anti-osteoporosis agent-3 (Compound 11), a PMSA derivative, is an anti-osteoporosis agent. Anti-osteoporosis agent-3 inhibits osteoclastogenesis with an IC50 value of 322.9 nM in vitro. Anti-osteoporosis agent-3 also blocks the formation of F-action belts and bone resorption .
    Anti-osteoporosis agent-3
  • HY-P1189
    Echistatin

    		Integrin Metabolic Disease Inflammation/Immunology
    Echistatin, the smallest active RGD protein belonging to the family of disintegrins that are derived from snake venoms, is a potent inhibitor of platelet aggregation. Echistatin is a potent inhibitor of bone resorption in culture. Echistatin is a potent antagonist of αIIbβ3, αvβ3 and α5β1 .
    Echistatin
  • HY-P1189A
    Echistatin TFA

    		Integrin Metabolic Disease Inflammation/Immunology
    Echistatin TFA, the smallest active RGD protein belonging to the family of disintegrins that are derived from snake venoms, is a potent inhibitor of platelet aggregation. Echistatin is a potent inhibitor of bone resorption in culture. Echistatin is a potent antagonist of αIIbβ3, αvβ3 and α5β1 .
    Echistatin TFA
  • HY-112499
    Menaquinone-7

    Vitamin K2-7; Vitamin K2(35); Vitamin MK-7

    		 Others Cardiovascular Disease
    Menaquinone-7 (Vitamin K2-7), belongs to a class of K2-vitamin homologs (orally active), is originally discovered as the anti-hemorrhagic factors. Menaquinone-7 inhibits osteoclast bone resorption in vitro and stimulates bone formation in femoral tissue of aged female rats. Menaquinone-7 has a well-researched potential in the prevention of aging-induced bone degeneration. Menaquinone-7 is also a pharmacological option for activating Gla matrix protein and intervening in the progression of calcific aortic stenosis (CAVS) .
    Menaquinone-7
  • HY-152262
    LXRβ agonist-4

    		LXR Inflammation/Immunology
    LXRβ agonist-4 is a potent, orally active Liver X receptors (LXRs) agonist with an IC50 value of 0.0078 μM for LXRβ. LXRβ agonist-4 inhibits RANKL-induced osteoclast differentiation and bone resorption. LXRβ agonist-4 can be used in research of osteoporosis .
    LXRβ agonist-4
  • HY-50887
    L-873724

    		Cathepsin Metabolic Disease
    L-873724 is a potent, orally bioavailable, selective and reversible non-basic cathepsin K inhibitor, with IC50s of 0.2, 178, 264, and 5239 nM for cathepsin K, cathepsin S, cathepsin L, cathepsin B, respectively . L-873724 also exhibits an IC50 of 0.5 nM for rabbit cathepsin K. L-873724 inhibits bone resorption .
    L-873724
  • HY-112499R
    Menaquinone-7 (Standard)

    Vitamin K2-7(Standard); Vitamin K2(35)(Standard); Vitamin MK-7 (Standard)

    		 Others Cardiovascular Disease
    Menaquinone-7 (Standard) is the analytical standard of Menaquinone-7. This product is intended for research and analytical applications. Menaquinone-7 (Vitamin K2-7), belongs to a class of K2-vitamin homologs (orally active), is originally discovered as the anti-hemorrhagic factors. Menaquinone-7 inhibits osteoclast bone resorption in vitro and stimulates bone formation in femoral tissue of aged female rats. Menaquinone-7 has a well-researched potential in the prevention of aging-induced bone degeneration. Menaquinone-7 is also a pharmacological option for activating Gla matrix protein and intervening in the progression of calcific aortic stenosis (CAVS) .
    Menaquinone-7 (Standard)
  • HY-135594
    4'-Raloxifene-β-D-glucopyranoside

    		Estrogen Receptor/ERR Metabolic Disease
    4'-Raloxifene-β-D-glucopyranoside, a metabolite of Raloxifene, is a benzothiophene glucuronidated at the 4' postion. 4'-Raloxifene-β-D-glucopyranoside is a selective and orally active estrogen receptor antagonist. 4'-Raloxifene-β-D-glucopyranoside can be used for inhibiting bone loss and resorption, and lowering lipid levels. 4'-Raloxifene-β-D-glucopyranoside, example 5, is extracted from patent US5567820A .
    4'-Raloxifene-β-D-glucopyranoside
  • HY-135595
    6-Raloxifene-β-D-glucopyranoside

    		Estrogen Receptor/ERR Drug Metabolite Metabolic Disease
    6-Raloxifene-β-D-glucopyranoside, a derivative of Raloxifene, is a benzothiophene glucuronidated at the 6' postion. 6-Raloxifene-β-D-glucopyranoside is a selective and orally active estrogen receptor antagonist. 6-Raloxifene-β-D-glucopyranoside can be used for inhibiting bone loss and resorption, and lowering lipid levels. 6'-Raloxifene-β-D-glucopyranoside, compound Ia, is extracted from patent US5567820A .
    6-Raloxifene-β-D-glucopyranoside
  • HY-162280
    PROTAC BTK Degrader-9

    		PROTACs RANKL/RANK Nuclear Factor of activated T Cells (NFAT) Btk Cancer
    PROTAC BTK Degrader-9 (compound 23) is a PROTAC degrader that effectively targets BTK. PROTAC BTK Degrader-9 downregulates the BTK-PLCγ2-Ca 2+-NFATc1 signaling pathway activated by RANKL. Thus, PROTAC BTK Degrader-9 was able to inhibit osteoclastogenesis and attenuate alveolar bone resorption in a mouse periodontitis model .
    PROTAC BTK Degrader-9
  • HY-N1746
    (2S)-2'-Methoxykurarinone

    2'-O-Methylkurarinone
    (2S)-2'-Methoxykurarinone, a compound isolated from the roots of Sophora flavescens, has anti-inflammatory, antipyretic, antidiabetic, and antineoplastic effects. (2S)-2'-Methoxykurarinone (MK) inhibits osteoclastogenesis and bone resorption through down-regulation of RANKL signaling. (2S)-2'-Methoxykurarinone (MK) displays cytotoxic activity against human myeloid leukemia HL-60 cells .
    (2S)-2'-Methoxykurarinone

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: